BioCentury | Feb 11, 2020
Product Development

Exelixis eyeing 2021 combo submission in prostate cancer following new readout

Exelixis believes newly released initial data from a Phase Ib trial cohort to treat prostate cancer could augur future results from the same twice-expanded cohort that could support a regulatory submission of cabozantinib plus Tecentriq...
BioCentury | Mar 7, 2019
Regulation

Gottlieb’s durable reforms

While most of the changes Scott Gottlieb has set in motion in just under two years as FDA commissioner are works in progress, and some may falter in his absence, an important number are well...
BioCentury | May 25, 2018
Clinical News

Dendreon takes Provenge earlier in prostate cancer

Dendreon Pharmaceuticals LLC announced it will study Provenge sipuleucel-T to prevent progression in men undergoing active surveillance for prostate cancer. Provenge comprises autologous dendritic cells loaded with a fusion protein of prostatic acid phosphatase and...
BioCentury | May 18, 2018
Clinical News

Dendreon takes Provenge earlier in prostate cancer

Dendreon Pharmaceuticals LLC announced it will study Provenge sipuleucel-T to prevent progression in men undergoing active surveillance for prostate cancer. Provenge comprises autologous dendritic cells loaded with a fusion protein of prostatic acid phosphatase and...
BioCentury | Apr 19, 2018
Product R&D

Automation navigation

Last year’s approvals of the first two CAR T therapies have prompted the field to get serious about industrializing manufacturing of the cells to improve reproducibility and lower costs. While stakeholders agree that automation will...
BioCentury | Mar 10, 2018
Product Development

Defining progress

Erleada apalutamide’s landmark approval established a new primary endpoint in prostate cancer that shortens the time it takes to run the trials by up to five years, and paves the way for treating disease before...
BioCentury | Sep 2, 2017
Strategy

Pathfinding for access

A pact with the Centers for Medicare & Medicaid Services for Novartis AG ’s CAR T therapy demonstrates leadership in new value-based drug pricing models. Kymriah tisagenlecleucel represents a milestone for three reasons. Its approval...
BioCentury | Jul 6, 2017
Company News

Sanpower completes acquisition of Dendreon from Valeant

Sanpower Group Co. Ltd. (Nanjing, China) completed the purchase of Dendreon Pharmaceuticals Inc. from Valeant Pharmaceuticals International Inc. (TSX:VRX; NYSE:VRX) for $819.9 million in cash. In February 2015, Valeant acquired bankrupt Dendreon's assets, including global...
BioCentury | Jun 30, 2017
Company News

Sanpower completes Dendreon acquisition

Sanpower Group Co. Ltd. (Nanjing, China) said it completed the purchase of Dendreon Pharmaceuticals Inc. from Valeant Pharmaceuticals International Inc. (TSX:VRX; NYSE:VRX) for $819.9 million in cash. In February 2015, Valeant acquired bankrupt Dendreon's assets,...
BioCentury | Jun 1, 2017
Clinical News

NewLink reports Phase II data for indoximod following Provenge in CRPC

In an abstract released ahead of the American Society of Clinical Oncology meeting in Chicago, NewLink Genetics Corp. (NASDAQ:NLNK) reported data from 35 evaluable patients with metastatic castration-resistant prostate cancer (CRPC) in a Phase II...
Items per page:
1 - 10 of 503